Intraperitoneal chemotherapy improves survival in ovarian cancer patients
Jan 22, 2006 - 10:43:37 PM
50-year-old method for delivering chemotherapy directly into the abdomen is making a comeback as investigators have found that it increases survival - by more than a year - in some women with advanced ovarian cancer. Results from a seven-year study of more than 400 patients nationwide are published in the January 5 issue of the New England Journal of Medicine.
Investigators randomly grouped women with newly diagnosed stage III ovarian cancer into two categories: those who would get all chemotherapy intravenously or those who would get chemotherapy both intravenously and through a spaghetti-like tube called a catheter that was inserted directly into the abdomen.
"The catheter allows us to bathe the entire abdominal area with a high concentration of chemotherapy for a long period of time, which appears to be better at destroying lingering cancer cells," says Deborah Armstrong, M.D., associate professor at the Johns Hopkins Kimmel Cancer Center and principal investigator for the study, which was conducted by the Gynecologic Oncology Group. While the abdominal area is the main site for ovarian cancer spread, Armstrong says that the intravenous round of chemotherapy is needed to catch cancer cells that may have spread outside the abdomen.
Overall survival for 205 patients receiving abdominal (or intraperitoneal) chemotherapy in the study was an average of 65.6 months, a 25 percent improvement over the intravenous-only group (49.7 months) of 210 patients. Similarly, relapse-free survival for those receiving intraperitoneal chemo was 23.8 months compared with 18.3 months for the intravenous-alone group, a 20 percent improvement.
"This is a significant improvement in survival for women with this disease, which is most often diagnosed at an advanced stage," notes Armstrong.
Side effects, such as suppressed blood counts and neurological problems, were significantly worse for the group receiving intraperitoneal (IP) chemotherapy. They reported poorer quality of life during their treatment. However, investigators noted that, one year later, patients in the IP group were on par with those only getting intravenous chemo. Nine patients died due to complications of the treatments; five from receiving IP chemotherapy and four from intravenous.
With these study results, the team of investigators supported by the national Gynecologic Oncology Group now can recommend IP therapy as the new standard for many women with ovarian cancer. According to Armstrong, many institutions have already adopted this practice.
Armstrong believes that some clinicians might be deterred by cost and lack of familiarity with IP. "We haven't done a cost analysis, but we expect IP therapy to be more expensive than intravenous - more drug and more staff time," she said.
Patients with adhesions or surgical complications, poor kidney function, and those who have had the left side of their colon removed during surgery are not ideal candidates for IP therapy.
It also is not clear whether the procedure has any benefit for recurrent disease or patients with large amounts of residual disease after surgery.
"The first and most important step is good surgery," says Robert Bristow, M.D., director of the Johns Hopkins Ovarian Cancer Center. "If you don't start with a surgeon specializing in gynecologic oncology who can effectively remove most of the tumor, then intraperitoneal chemotherapy may not work."
According to Armstrong, fewer than 50 percent of U.S. women with ovarian cancer seek a gynecologic oncology specialist for their surgery despite research showing better outcomes for this group.
IP chemotherapy was first studied half a century ago for colon cancer but never gained popularity for ovarian cancer despite several studies that hinted at survival benefits. The benefits were overshadowed by the promise of new chemotherapy drugs such as paclitaxel, one of the chemo drugs used in Armstrong's study.
The second chemotherapy agent used in the current study was cisplatin, a drug which most clinicians bypass in favor of carboplatin, a faster and better tolerated drug. But since it does not appear to penetrate tumors as well, most believe that carboplatin is not currently a drug-of-choice for IP therapy.
"Modern dosing techniques may reveal that may not be true, and we're conducting an early study of IP therapy with carboplatin," says Armstrong. Some investigators are also studying ways to add new agents that are highly specific for cancer cells into the IP regimen.
This study was funded by the Gynecologic Oncology Group.
In addition to Armstrong, authors include Brian Bundy, Ph.D., from the Gynecologic Oncology Group and Roswell Park Cancer Institute; Lari Wenzel, M.D., from the University of California at Irvine; Helen Q. Huang, M.D., from the Gynecologic Oncology Group; Rebecca Baergen, M.D., from the New-York Presbyterian Hospital; Shashikant Lele, M.D., from the Roswell Park Cancer Institute; Larry J. Copeland, M.D., from Ohio State University; Joan L. Walker, M.D., from the University of Oklahoma; and Robert A. Burger, M.D., from the University of California, Irvine.
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEJM, January 5, 2006, Vol. 354, Issue No. 1; pgs.34-43.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )